Knockdown of PKR expression by RNAi reduces pulmonary metastatic potential of B16-F10 melanoma cells in mice: Possible role of NF-κB

Cancer Letters

Volumn 258, Issue 1, 2007, Pages 118-125

  Delgado André, Nayara ^a   De Lucca, Fernando L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

B16 Melanoma; Cancer; Metastasis; NF B; PKR; RNA interference

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PLASMID VECTOR; PROTEIN KINASE; RNA DEPENDENT PROTEIN KINASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; DRUG EFFECT; EXPRESSION VECTOR; IN VITRO GENE TRANSFER; LUNG METASTASIS; MALE; MELANOMA; MELANOMA CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONTENT; RNA INTERFERENCE;

ANIMALS; BLOTTING, WESTERN; EIF-2 KINASE; LUNG NEOPLASMS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NF-KAPPA B; RNA, SMALL INTERFERING;

MUS;

EID: 35349014040     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.08.021     Document Type: Article

References (32)

1. Clemens M.J., and Elia A. The double-stranded RNA-dependent protein kinase PKR: structure and function. J. Interferon Cytokine Res. 17 (1997) 503-524
2. Watanabe M.A.E., Souza L.R., Murad J.M., and De Lucca F.L. Activation of the RNA-dependent protein kinase of lymphocytes by regulatory RNAs: implications for immunomodulation in HIV infection. Curr. HIV Res. 3 (2005) 329-337
3. García M.A., Gil J., Ventoso I., Guerra S., Domingo E., Rivas C., and Esteban M. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol. Mol. Biol. Rev. 70 (2006) 1032-1060
4. Bommer U., Borovjagin A.V., Greagg M.A., Jeffrey I.W., Russell P., Laing K.G., Lee M., and Clemens M.J. The mRNA of the translationally controlled tumor protein P23/TCTP is a highly structured RNA, which activates the dsRNA-dependent protein kinase PKR. RNA 8 (2002) 478-496
5. De Lucca F.L., Sales V.S.F., Souza L.R., Murad J.M., and Watanabe M.A.E. Regulatory RNA induces the production of IFN-γ, but not IL-4 in human lymphocytes: role of RNA-dependent protein kinase (PKR) and NF-κB. Mol. Cell. Biochem. 247 (2003) 211-217
6. Murad J.M., Souza L.R., and De Lucca F.L. PKR activation by a non-coding RNA expressed in lymphocytes of mice bearing B16 melanoma. Blood Cells Mol. Dis. 37 (2006) 128-133
7. Koromilas A.E., Roy S., Barber G.N., Katze M.G., and Sonenberg N. Malignant transformation by a mutant of the IFN-inducible ds RNA-dependent protein kinase. Science 257 (1992) 1685-1689
8. Meurs E.F., Galabru J., Barber G.N., Katze M.G., and Hovanessian A. Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. USA 190 (1993) 232-236
9. Donzé O., Jagus R., Koromilas A.E., Hershey J.W., and Sonenberg N. Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells. EMBO J. 14 (1995) 3828-3834
10. Yang Y.L., Reis L.F., Pavlovic J., Aguzzi A., Schäfer R., Kumar A., Williams B.R., Aguet M., and Weissmann C. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J. 14 (1995) 6095-6106
11. Abraham N., Stojdl D.F., Duncan P.I., Méthot N., Ishii T., Dubé M., Vanderhyden B.C., Atkins H.L., Gray D.A., McBurney M.W., Koromilas A.E., Brown E.G., Sonenberg N., and Bell J.C. Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR. J. Biol. Chem. 274 (1999) 5953-5962
12. Kim S.H., Gunnery S., Choe J.K., and Mathews M.B. Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR. Oncogene 21 (2002) 8741-8748
13. Nussbaum J.M., and Gunnery S. Transcriptional upregulation of interferon-induced protein kinase, PKR, in breast cancer. Cancer Lett. 196 (2003) 207-216
14. Roh M.S., Kwak J.Y., Kim S.J., Lee H.W., Kwon H.C., Hwang T.H., Choi P.J., and Hong Y.S. Expression of double-stranded RNA-activated protein kinase in small-size peripheral adenocarcinoma of the lung. Pathol. Int. 55 (2005) 688-693
15. Sui G., Soohoo C., Affar E.B., Gay F., Shi Y., Forrester W.C., and Shi Y. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA 99 (2002) 5515-5520
16. Elbashir S.M., Harborth J., Weber K., and Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26 (2002) 199-213
17. Dorsett Y., and Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat. Rev. Drug. Discov. 3 (2004) 318-329
18. Gao L., Zhang L., Hu J., Li F., Shao Y., Zhao D., Kalvakolanu D.V., Kopecko D.J., Zhao X., and Xu D.-Q. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin. Cancer Res. 11 (2005) 6333-6341
19. Amarzguioui M., Peng Q., Wiiger M.T., Vasovic V., Babaie E., Holen T., Nesland J., and Prydz H. Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells. Clin. Cancer Res. 12 (2006) 4055-4061
20. Takei Y., Kadomatsu K., Yuzawa Y., Matsuo S., and Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 64 (2004) 3365-3370
21. Yano J., Hirabayashi K., Nakagawa S., Yamaguchi T., Nogawa M., Kashimori I., Naito H., Kitagawa H., Ishiyama K., Ohgi T., and Irimura T. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin. Cancer Res. 10 (2004) 7721-7726
22. Lee J.H., Cho E.S., Kim M., Seo Y., Kho D.H., Chung I.J., Kook H., Kim N.S., Ahn K.Y., and Kim K.K. Suppression of progression and metastasis of established colon tumors in mice by intravenous delivery of short interfering RNA targeting KITENIN, a metastasis-enhancing protein. Cancer Res. 65 (2005) 8993-9003
23. Cullen B.R. Induction of stable RNA interference in mammalian cells. Gene Ther. 13 (2006) 503-508
24. Nicolson G.L., Brunson K.W., and Fidler I.J. Specificity of arrest, survival, and growth of selected metastatic variant cell lines. Cancer Res. 38 (1978) 4105-4111
25. Zheng X., and Bevilacqua P.C. Activation of the protein kinase PKR by short double-stranded RNAs with single-stranded tails. RNA 10 (2004) 1934-1945
26. Sledz C.A., and Williams B.R.G. RNA interference and double-stranded RNA-activated pathways. Biochem. Soc. Trans. 32 (2004) 952-956
27. Veer M.J., Sledz C.A., and Williams B.R.G. Detection of foreign RNA: implications for RNAi. Immunol. Cell Biol. 83 (2005) 224-228
28. Puthenveetil S., Whitby L., Ren J., Kelnar K., Krebs J.F., and Beal P.A. Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification. Nucleic Acids Res. 34 (2006) 4900-4911
29. Gil J., Alcami J., and Esteban M. Activation of NF-kappaB by the dsRNA-dependent protein kinase, PKR involves the I-kappa B kinase complex. Oncogene 19 (2000) 1369-1378
30. Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 18 (2000) 621-663
31. Ravi R., and Bedi A. NF-kappaB in cancer - a friend turned foe. Drug Resist. Updat. 7 (2004) 53-67
32. Thompson J.E., Phillips R.J., Erdjument-Bromage H., Tempst P., and Ghosh S. IκB-β regulates the persistent response in a biphasic activation of NF-κB. Cell 80 (1995) 573-582